COST-EFFECTIVENESS ANALYSIS OF ORAL N -ACETYLCYSTEINE AS A PREVENTIVE TREATMENT IN CHRONIC BRONCHITIS

This publication has 20 references indexed in Scilit:

• Trying to do better than average: a commentary on ‘statistical inference for cost-effectiveness ratios’
  Health Economics, 1997
• Pharmacoeconomics: basic concepts and terminology
  British Journal of Clinical Pharmacology, 1997
• The future of pharmacoeconomics: bridging science and practice
  Clinical Therapeutics, 1996
• Prevalence and treatment of chronic airways obstruction in adults over the age of 45.
  Thorax, 1996
• Sensitivity analysis in economic evaluation: A review of published studies
  Health Economics, 1995
• Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis
  Respiratory Medicine, 1994
• In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care
  Medical Care, 1994
• Oral fabrol (oral N-acetylcysteine) in chronic bronchitis
  Respiratory Medicine, 1987
• Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee.
  Thorax, 1985
• Patterns of drug taking in patients with chronic airflow obstruction
  Postgraduate Medical Journal, 1985